The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
Information source: University of Southern California
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cognitive Impairment; Hypertension; Aging
Intervention: candesartan (Drug); lisinopril (Drug); hydrochlorothiazide (Drug); nifedipine, long acting (Drug); metoprolol, long-acting (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: University of Southern California Official(s) and/or principal investigator(s): Ihab Hajjar, MD, Principal Investigator, Affiliation: University of Southern California
Summary
The purpose of this study is to examine the effects of blood pressure medications on
cognition and blood flow in hypertensive elderly patients with cognitive impairment. The
hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an
angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of
further cognitive decline, improved cerebral blood flow and its regulation, and preserved
physical function as compared to treatment with a diuretic (HCTZ), independent of blood
pressure level.
Clinical Details
Official title: The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Cognitive Assessment: Trail Making Test Part BCognitive Assessment: Hopkins Verbal Learning- Immediate Recall Cognitive Assessment: Forward Digit Span Test
Secondary outcome: Blood Pressure Outcome: Systolic BPBlood Flow Velocity, Sitting
Detailed description:
There is mounting evidence that hypertension, which affects more than 65% of the US elderly
population, accelerates cognitive decline and increases the risk of functional disability
among older individuals. Hypertension is also associated with cerebral blood flow reduction
and dysregulation which contribute to further cognitive and functional impairment. Drugs
that inhibit angiotensin II (ACEI and ARB) are commonly used antihypertensives and may have
a protective effect on cognitive function, cerebral blood flow and physical function
compared to other antihypertensives such as hydrochlorothiazide (HCTZ).
A total of 100 individuals will be recruited for this pilot 3-arm randomized study to
investigate the effects of: (i) 12 months treatment with candesartan (ARB) compared to
hydrochlorothiazide (HCTZ) and (ii) 12 months treatment with lisinopril (ACEI) compared to
HCTZ and (iii) to estimate the effect size difference between lisinopril and losartan on
cognition, cerebral blood flow regulation, and functional measures in a sample of elderly
hypertensive individuals with objective evidence of cognitive impairment.
Eligibility
Minimum age: 60 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 60 years or older
- Hypertension
- Cognitive criteria: score either 10 or less out of 15 for the executive clock draw
test 1 (CLOX1) or less than or equal to 1 standard deviation from the corresponding
age specific mean on the immediate memory subtest
Exclusion Criteria:
- Intolerance to ACEI or ARB
- History of congestive heart failure
- History of diabetes mellitus
- History of stroke (less than 6 months)
Locations and Contacts
University of Southern California, Los Angeles, California 90033, United States
Hebrew SeniorLife, Boston, Massachusetts 02131, United States
Additional Information
Related publications: Lipsitz LA, Gagnon M, Vyas M, Iloputaife I, Kiely DK, Sorond F, Serrador J, Cheng DM, Babikian V, Cupples LA. Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects. Hypertension. 2005 Feb;45(2):216-21. Epub 2005 Jan 17. Hajjar I, Hart M, Milberg W, Novak V, Lipsitz L. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr. 2009 Nov 18;9:48. doi: 10.1186/1471-2318-9-48.
Starting date: January 2008
Last updated: January 14, 2013
|